You are about to leave the BeOne UK site.
You may see information that is not specific to your region.
You are about to leave the BeOne UK site.
You may see information that is not specific to your region.
Please select the most appropriate option below:
0525-NP-PRC-049 | June 2025
In 2024 we gave a grant of £20,000 to support their Healthcare Professional Education training course in Oxford and patient support materials. Our funding represented less than 1% of their overall income.
In 2024 we gave a grant of £39,976 to support an additional part time telephone helpline nurse. This was the first annual payment of a three-year agreement. Our funding represented 1.62% of their overall income.
In 2024 we gave a grant of £15,000 to help support the expansion of their clinical trials support service. Our funding represented less than 1% of their overall income.
In 2024 we gave a grant of £135,000 to help with projects to strengthen their patient support services. Our funding represented 28% of their overall income.
In 2024 we gave a grant of £20,000 to help support their 20th anniversary patient conferences and educational materials. Our funding represented 9.89% of their overall income.
0625-NP-PRC-007 | June 2025
We're pleased to share that
BeiGene is now BeOne Medicines UK, Ltd.
While our name has changed, our values and purpose remain the same.
We're as committed as ever to our mission: to build the first next-generation oncology company - one that expands access to the highest quality therapies for more people around the world through courage, persistent innovation, and by challenging the status quo.
This change does not affect any existing agreements or day-to-day operations. You can continue to rely on the same dedication, collaboration, and shared goals that define our company.
Look out for our new logo - it reflects our renewed identity and vision, and symbolises the goals we're striving toward together.
0625-NP-PRC-031 | June 2025